![Ask the Expert with Amer Zeidan](https://oncodaily.com/pub/uploads/2024/05/download-8-986x1280-1.jpg)
Photo from Amer Zeidan/LinkedIn
Jul 27, 2024, 12:01
Ask the Expert with Amer Zeidan
Amer Zeidan, Associate Professor of Department of Internal Medicine and Hematology at Yale School of Medicine, shared on X:
“Ask the Expert: COMMANDS Trial Results of First-Line Luspatercept Versus Epoetin Alfa in Transfusion-Dependent Patients With Lower-Risk Myelodysplastic Syndromes – Personalized Medicine in Oncology.”
Read Further.
Source: Amer Zeidan/X